Free weekly newsletter
Get the free weekly contract digest
The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Sparian Biosciences Awarded $19.5 Million NIH/NIDA Grant for SBS-226 Development for Opiate Use Disorder
Nov 14, 2024•over 1 year ago
Contract Type
partnership
New YorkBiotechnologyHealth CareTherapeuticsBiopharmaDescription
Sparian Biosciences, Inc. has been awarded a $19.5 million, five-year grant from NIH/NIDA to fund the development of SBS-226, a first-in-class dual mu opiate receptor (MOR) partial agonist and delta opiate receptor (DOR) full antagonist in development for opiate use disorder (OUD) and opiate withdrawal syndrome (OWS). SBS-226 aims to replace the current standard of care as a more effective and safer option for patients.
Related People
Suggested for you
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months